Molecular Subtyping of Primary Prostate Cancer Reveals Specific and Shared Target Genes of Different ETS Rearrangements  by Paulo, Paula et al.
Molecular Subtyping of Primary
Prostate Cancer Reveals Specific
and Shared Target Genes of
Different ETS Rearrangements1,2
Paula Paulo*,†,‡,§, Franclim R. Ribeiro*,†,‡,§,
Joana Santos*,†, Diana Mesquita*,†,
Mafalda Almeida*,¶, João D. Barros-Silva*,†,
Harri Itkonen#, Rui Henrique¶,**,††,
Carmen Jerónimo*,¶,††, Anita Sveen‡,§,
Ian G. Mills‡,#,‡‡, Rolf I. Skotheim‡,§,
Ragnhild A. Lothe‡,§ and Manuel R. Teixeira*,†,§,††
*Department of Genetics, Portuguese Oncology Institute,
Porto, Portugal; †Group of Cancer Genetics, Research
Centre of the Portuguese Oncology Institute, Porto,
Portugal; ‡Department of Cancer Prevention, Institute for
Cancer Research, Oslo University Hospital, Oslo, Norway;
§Centre for Cancer Biomedicine, University of Oslo, Oslo,
Norway; ¶Group of Cancer Epigenetics, Research Centre
of the Portuguese Oncology Institute, Porto, Portugal;
#Centre for Molecular Medicine Norway, Nordic European
Molecular Biology Laboratory Partnership, Biotechnology
Centre, University of Oslo, Oslo, Norway; **Department of
Pathology, Portuguese Oncology Institute, Porto, Portugal;
††Institute of Biomedical Sciences Abel Salazar, University
of Porto, Porto, Portugal; ‡‡Department of Urology, Oslo
University Hospital, Oslo, Norway
Abstract
This work aimed to evaluate whether ETS transcription factors frequently involved in rearrangements in prostate
carcinomas (PCa), namely ERG and ETV1, regulate specific or shared target genes. We performed differential ex-
pression analysis on nine normal prostate tissues and 50 PCa enriched for different ETS rearrangements using
exon-level expressionmicroarrays, followed by in vitro validation using cell linemodels.We found specific deregulation
of 57 genes in ERG-positive PCa and 15 genes in ETV1-positive PCa, whereas deregulation of 27 genes was shared in
both tumor subtypes. We further showed that the expression of seven tumor-associated ERG target genes (PLA1A,
CACNA1D, ATP8A2, HLA-DMB, PDE3B, TDRD1, and TMBIM1) and two tumor-associated ETV1 target genes (FKBP10
and GLYATL2) was significantly affected by specific ETS silencing in VCaP and LNCaP cell line models, respectively,
Abbreviations: AR, androgen receptor; DAC, 5-aza-2′deoxycytidine; NPT, normal prostate tissue; PCA, principal components analysis; PCa, prostate carcinoma; qMSP, quan-
titative methylation-specific PCR; qRT-PCR, quantitative real-time polymerase chain reaction; shRNA, short hairpin RNA; siRNA, small interfering RNA; TSA, Trichostatin A
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whereas the expression of three candidate ERG and ETV1 shared targets (GRPR, KCNH8, and TMEM45B) was
significantly affected by silencing of either ETS. Interestingly, we demonstrate that the expression of TDRD1, the
topmost overexpressed gene of our list of ERG-specific candidate targets, is inversely correlated with the methyla-
tion levels of a CpG island found at −66 bp of the transcription start site in PCa and that TDRD1 expression
is regulated by direct binding of ERG to the CpG island in VCaP cells. We conclude that ETS transcription factors
regulate specific and shared target genes and that TDRD1, FKBP10, and GRPR are promising therapeutic targets and
can serve as diagnostic markers for molecular subtypes of PCa harboring specific fusion gene rearrangements.
Neoplasia (2012) 14, 600–611
Introduction
Genomic rearrangements involving five members of the ETS family
of transcription factors have been found in prostate carcinomas
(PCa). Rearrangements of ERG and ETV1 were first described by
Tomlins et al. [1] and are found in approximately 50% and 5% to
10% of PCa, respectively [2,3]. Rearrangements of ETV4 and ETV5
were later identified in a small proportion of PCa, representing less
than 5% of all rearranged cases [4–7]. Recently, we identified FLI1 as
the fifth member of the ETS family of transcription factors involved
in gene fusions in PCa, being fused to the SLC45A3 gene [8].
The products of specific chimeric genes could be ideal therapy
targets, but the nuclear localization of the aberrant ETS proteins
makes them a difficult therapy target in vivo [9]. Therefore, it is
important to characterize in detail the downstream molecular targets
of each of the aberrant transcription factors, not only to understand
the deregulated signaling pathways but also because some of them
may turn out to be more amenable to targeted therapy. In vitro stud-
ies revealed that ERG activates plasminogen and Wnt pathways to
promote degradation of the extracellular matrix and decrease cell
adhesion, but very few genes have been validated as direct ERG
targets [10–12]. Because ETV1 rearrangements are considerably less
frequent than those of ERG, reports focusing on the oncogenic effec-
tors of ETV1 overexpression are scarce and not based in the expres-
sion profile observed in ETV1 rearrangement-positive tumors, with
some in vitro and in vivo models linking overexpression of ETV1
with the invasion potential of cancer cells by activation of matrix
metalloproteinases and integrins [13–15].
Despite the apparently overlapping oncogenic potential of ERG
and ETV1 gene fusions, it has not been established whether different
ETS transcription factors have shared or specific downstream targets.
We addressed this issue by using exon-level expression arrays in a
series of 50 PCa enriched for different ETS rearrangements and
validated the findings using in vitro cell line models.
Materials and Methods
Prostate Tissue Samples
We used a series of 50 tumor samples selected from a consecutive
series of 200 clinically localized PCa that were previously typed for
ETS rearrangements [8]. The 50 prostatectomy samples were selected
to represent the various molecular subtypes of PCa, namely 21 samples
with ERG rearrangement, 13 samples with ETV1 rearrangement,
2 samples with other ETS rearrangements (one with ETV4 and one
with ETV5 rearrangements), and 14 samples without known ETS
rearrangement. For control purposes, nine normal prostate tissues
(NPTs) were collected from cystoprostatectomy specimens of bladder
cancer patients. This study was approved by the institutional review
board, and informed consent was obtained from all subjects.
Prostate Cell Lines
VCaP and PNT2 cells were acquired from the European Collec-
tion of Cell Cultures (Sigma-Aldrich, St Louis, MO). LNCaP, PC3,
and DU145 cells were acquired from the German Resource Centre
for Biological Material (DSMZ, Braunschweig, Germany). 22Rv1
cells were kindly provided by Dr David Sidransky from the Johns
Hopkins University School of Medicine. The virus packaging Retro-
Pack PT67 cell line was acquired from Clontech Laboratories, Inc
(Saint-Germain-en-Laye, France). All prostate cell lines were cultured
under the recommended conditions, being karyotyped by G banding
for validation purposes and tested for Mycoplasma spp. contamina-
tion (PCR Mycoplasma Detection Set; Clontech Laboratories). After
transfection, cells were grown in medium supplemented with G418
(300 μg/ml; GIBCO by Life Technologies, Carlsbad, CA) or puromycin
(5 μg/ml, Clontech Laboratories), as appropriate.
Gene Expression Microarrays
RNA was extracted from tissue samples using TRIzol (Invitrogen
by Life Technologies, Carlsbad, CA), as previously described [8], and
1 μg of RNA was processed into complementary DNA (cDNA) and
hybridized to GeneChip Human Exon 1.0 ST arrays, following the
manufacturer’s recommendations. The Affymetrix Expression Console
v1.1 software was used to obtain gene-level RMA-normalized expres-
sion values for the core probe sets only. We used analysis of variance
in Partek Genomics Suite 6.4 (Partek, Inc, St Louis, MO) to identify
differentially expressed genes among the different sample groups. The
two PCa with ETV4 and ETV5 rearrangements were not included in
this analysis. Specific ERG target genes were identified from genes
differentially expressed between each of the three group comparisons:
NPT versus ERG-positive PCa, ETS-negative PCa versus ERG-positive
PCa and ETV1-positive PCa versus ERG-positive PCa. To select specific
ETV1 target genes, the same approach was applied comparing NPT
versus ETV1-positive PCa, ETS-negative PCa versus ETV1-positive
PCa and ERG-positive PCa versus ETV1-positive PCa. Targets common
to ERG and ETV1 rearrangements were identified from the differen-
tially expressed genes in each of the four group comparisons: NPT versus
ERG-positive PCa, NPT versus ETV1-positive PCa, ETS-negative PCa
versus ERG-positive PCa and ETS-negative PCa versus ETV1-positive
PCa. Only differentially expressed genes with a false discovery rate less
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than 5% and P < .02 between each two-group comparison were re-
tained for further analyses. Principal components analysis (PCA) was
performed with Partek Genomics Suite 6.4 and hierarchical clustering
with MultiExperiment Viewer 4.6.0. Hierarchical clustering was per-
formed using Spearman rank correlation and average linkage optimized
for gene leaf order.
Transient Silencing of ERG Expression in VCaP Cells
To induce down-regulation of ERG expression in VCaP cells we used
small interfering RNAs (siRNAs) as described by others [12]. The
SMART-pool siRNA directed to ERG (M-003886-01; Dharmacon,
Thermo Fisher Scientific, Rockford, IL) and the siCONTROL Non-
Targeting RNA (D-001210-01; Dharmacon) were transfected into
VCaP cells using Oligofectamine (Invitrogen). After 48 and 72 hours,
RNA and protein extractions were performed using the TriplePrep Kit
(GEHealthcare, Cleveland, OH). Expression data of VCaP-siERG cells
were normalized to VCaP-siCont for each time point.
Generation of Plasmid Constructs for Stable Silencing and
De Novo Overexpression
To generate constructs for stable silencing of ETV1, specific short
hairpin RNA (shRNA) sequences were selected and designed using
the RNAi Target Sequence Selector and the shRNA Sequence De-
signer, respectively (both from Clontech Laboratories). shETV1-553
(5′-GATCCGCTCATACACCGAAACCTGATTCAAGA GAT-
CAGGTTTCGGTGTATGAGTTTTTTACGCGTG-3′) and
shETV1-1037 (5′-GATCCACAAGAGCCAGGAATGTATTTCAA-
GAGAATACATTCCTGGCTCTTGTTTTTTTACGCGTG-3′)
oligonucleotides were acquired from Sigma-Aldrich, annealed, and
cloned into the pSIREN-Retro-Q vector (Clontech Laboratories) at
BamHI and EcoRI restriction sites, together with the negative control
shNeg (Clontech Laboratories). To generate constructs for de novo
overexpression of ETV1 and ERG, full-length ETV1 CDS and trun-
cated ERG CDS (ΔERG and ΔERGΔ8) were amplified from LNCaP
and VCaP cells, respectively, using In-fusion primers (Table W1) and
the Phusion Taq DNA polymerase (Finnzymes, Vantaa, Finland).
Polymerase chain reaction (PCR) products were cloned into the
pMSCVneo vector (Clontech Laboratories) at BglII and EcoRI restric-
tion sites using the In-Fusion Advantage PCR cloning kit (Clontech
Laboratories), according to instructions. The pMSCVneo-ETV1 con-
struct contains the ETV1 full-length CDS (ENST00000242066), as
expected; the pMSCVneo-ΔERG contains the expected CDS derived
from the type III TMPRSS2-ERG transcript [16] and pMSCVneo-
ΔERGΔ8 contains the alternatively spliced transcript lacking 72 bp
(exon 8) [17,18].
Stable Silencing of ETV1 in LNCaP Cells
To silence the expression of ETV1 in LNCaP cells, PT67 cells
were transfected with each construct and also with the control vector
pSIREN-shNeg using the CaPO4-based transfection method, fol-
lowing Clontech’s recommendations (protocol no. PT3132-1, version
no. PR631543). Transfected cells were selected with puromycin and
expanded. LNCaP cells were exposed to viral medium for 8 hours and
allowed to recover for 24 hours in regular growth conditions. Stable
LNCaP-shETV1 and LNCaP-shNeg populations were obtained with
puromycin-selective pressure. Two independent, low ETV1 expression
clones (LNCaP-shETV1-C1 and LNCaP-shETV1-C2) were isolated
and used for further analyses.
Stable Overexpression of ETV1 and ΔERG Isoforms in
PNT2 Cells
For stable expression of the ETV1 and ΔERG isoforms described,
PT67 cells were transfected with pMSCV constructs and with the
empty vector pMSCVneo as previously described. Transfected cells were
selected with G418 and expanded. Transduction of PNT2 cells was
carried out as previously described for LNCaP cells. A control population
(PNT2-Neo) and two independent populations showing overexpres-
sion of either ETV1 (PNT2-ETV1-A and PNT2-ETV1-B) or ΔERG
isoforms (PNT2-ΔERG-A, PNT2-ΔERG-B, PNT2-ΔERGΔ8-A and
PNT2-ΔERGΔ8-B) were obtained with G418-selective pressure.
In Silico Selection of Target Genes for Further Validation
We used the expression data of VCaP, LNCaP, PC3, and DU145
cell lines available from Taylor et al. that can be accessed from the
Gene Expression Omnibus (GSE21034) to select the candidate target
genes where differential expression was specific of the cell line models
harboring ETS rearrangements, taking into consideration the candi-
date target genes resulting from the microarray analysis of the prostate
tumor samples. Using the RMA-normalized signal intensity values, ERG-
associated genes were selected as those differentially upregulated or down-
regulated at least 1.5-fold in VCaP cells comparing with the others.
Similarly, ETV1-associated genes were those differentially upregulated
or downregulated at least 1.5-fold in LNCaP cells comparing with the
others, and target genes shared by ERG and ETV1 rearrangements were
those differentially upregulated or downregulated at least 1.5-fold in
VCaP or LNCaP cells comparing with PC3 and DU145 cell lines.
Quantitative Real-time Polymerase Chain Reaction
RNA was extracted from subconfluent cell lines using the RNeasy
mini kit (Qiagen, GmbH,Hilden, Germany). cDNAwas obtained from
1 μg of RNA using oligo-dT primers and the H-minus RevertAid cDNA
synthesis kit (Fermentas, Ontario, Canada), according to the manufac-
turer’s instructions. Expression of target genes was quantified using pre-
developed TaqMan assays from Applied Biosystems (Life Technologies,
Foster City, CA) (Table W1) and normalized to the expression of the
GUSB housekeeping gene using the comparative C t method [19].
Western Blot Analysis
Protein was extracted from subconfluent cells using RIPA lysis buffer
in the presence of protease inhibitors (Santa Cruz Biotechnology, Inc,
Heidelberg, Germany), and concentration was determined by the BCA
protein assay (Thermo Fisher Scientific), following the manufacturer’s
recommendations. Specific detection of ERG and ETV1 was achieved
by incubation with rabbit anti-ERG (1:1000; Epitomics, Burlingame,
CA) and mouse anti-ETV1 (1:500; Sigma-Aldrich) monoclonal anti-
bodies, respectively. An anti–β-actin monoclonal antibody (1:8000;
Sigma-Aldrich) was used to control protein loading.
Bisulfite Treatment and Quantitative Methylation-Specific
PCR of TDRD1
Genomic DNA was extracted from prostate tissues and cell lines
using a standard technique comprising digestion with proteinase K
(20 mg/ml) in the presence of 10% SDS at 55°C, followed by phenol-
chloroform extraction and precipitation with 100% ethanol [20]. In 4
of the 50 PCa samples (1 ERG-positive, 1 ETV1-positive, and the 2
samples with other ETS rearrangements), it was not possible to obtain
DNA. One microgram of DNA was submitted to bisulfite modification
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using the EZ DNA Methylation Gold Kit (Zymo Research, Orange,
CA) following the manufacturer’s instructions. Bisulfite-modified
DNA was amplified by quantitative methylation-specific PCR (qMSP)
using TaqMan technology [21]. Specific TDRD1 primers and TaqMan
probe were designed using the Methyl Primer Express Software v1.0
(Applied Biosystems; Table W1). β-Actin (ACTB) was used as an inter-
nal reference gene to normalize for DNA input and qMSP reaction was
performed as previously described [22]. Methylation levels for each
sample were obtained from calibration curves constructed using serial
dilutions of bisulfite-modified CpGenome Universal Methylated DNA
(Millipore, Billerica, MA). TDRD1 methylation levels were obtained
after normalization to ACTB.
Bisulfite Sequencing
To obtain detailed information about the methylation status of
CpG sites in the CpG island found in the TDRD1 promoter, bisulfite-
sequencing PCR primers (Table W1) that span the region of interest
were tested in bisulfite-modified DNA from VCaP, LNCaP, PC3,
DU145, 22Rv1, and PNT2 cells. PCR was performed as previously
described [23].
Chromatin Immunoprecipitation and Quantitative PCR
Transcription factor–dependent gene expression is associated with
the recruitment of transcription factors to regulatory sequences. This
is detected commonly through the use of chromatin immunoprecipita-
tion and, where sites are known or predicted, through quantitative PCR
(qPCR) for the bound regions. We used VCaP cells and the rabbit
anti-ERG monoclonal antibody (Epitomics) to detect ERG binding
to the promoter of candidate target genes. For each immunoprecipita-
tion with the EZ-Magna chromatin immunoprecipitation (ChIP) G kit
(Millipore), 2 × 106 cells were used, following the manufacturer’s in-
structions [24,25]. We used two approaches to identify candidate sites
within the promoter regions. One approach was to mine the ChIP-Seq
data set available from Yu et al. [26] for ERG generated in the VCaP
cell line (GSE14092, sample GSM353647). Processed sequencing files
were uploaded into the UCSC genome browser and aligned to build
hg18. Gene proximal sites were then selected. In addition, we also used
in silico prediction by uploading promoter sequences into ConSite—
http://asp.ii.uib.no:8090/cgi-bin/CONSITE/consite/ [27]. Overall,
four promoter regions were analyzed for TDRD1 (−1207, −3196,
−7686, and −8768) and three for GRPR (−583, −1386, and −4858),
KCNH8 (−797, −1472, and −3506), and TMEM45B (−260, −2847,
and −5687). Primers were designed using the Primer3 online soft-
ware and acquired from Metabion (Martinsried, Germany). Prim-
ers for a negative control region were also included to correct for
unspecific binding (TableW1) [28]. qPCR was performed using Power
SYBR Green (Applied Biosystems), according to the manufacturer’s
recommendations. Results are shown as a fold enrichment of ERG
bound chromatin relative to IgG and corrected to the negative control
region [29].
Figure 1. Workflow applied to 9 NPTs and 50 PCa previously characterized for the presence of known ETS rearrangements to identify
both specific and shared ERG and ETV1 target genes by differential expression analysis. The two PCa with other ETS rearrangements
were not included in Partek Genomics Suite analysis.
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Figure 3. Validation of tumor-associated ERG target genes in cell line models. (A) Using siRNAs directed to ERG, a significant down-
regulation of ERG expression was achieved in VCaP cells, as evaluated both by qRT-PCR and by Western blot analyses at 48 and 72 hours
after transient transfection. (B) Of the eight tumor-associated ERG candidate target genes, seven were significantly deregulated after ERG
silencing, as evaluated by qRT-PCR. (C) De novo expression of two ΔERG isoforms was stably induced in the benign PNT2 prostate cells,
as shown both by qRT-PCR and Western blot analyses. (D) De novo expression of ΔERG isoforms was not sufficient to induce expression
of the tumor-associated ERG target genes in PNT2 cells. *P < .05. **P < .01. NS indicates not significant (P > .05).
Figure 2. PCA and hierarchical clustering of the expression profile obtained for normal controls (NPT) and PCa samples. (A and B) Sample
distribution obtained by PCA in Partek Genomics Suite using the full gene expression profile and the 99 gene panel obtained by differential
expression analysis, respectively. (C) Hierarchical clustering of the 9 NPT samples and the 50 PCa obtained with the RMA-normalized
expression data of the panel of 99 genes selected with Partek’s differential expression analysis. The nine NPTs are shown in black, the
ETS-negative PCa in gray, the ERG-positive PCa in red, the ETV1-positive PCa in dark purple, and the other ETS-positive PCa in light purple.
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Cell Line Treatment with Epigenetic Modulating Drugs
To evaluate whether TDRD1 promoter demethylation was regulated
by ERG, we treated PNT2 cells with de novo expression of ΔERG and
ETV1 with 1 μM of the DNA methyltransferases inhibitor 5-aza-2′
deoxycytidine (DAC; Sigma-Aldrich) and with 0.5 μM of the histone
deacetylase inhibitor Trichostatin A (TSA; Sigma-Aldrich), both indi-
vidually and in combination, as described by Costa et al. [23]. After 72
and 24 hours of treatment with DAC and TSA, respectively, DNA
and RNA were extracted using the TriplePrep Kit (GE Healthcare),
according to the manufacturer’s recommendations.
Statistical Analysis
To compare gene expression data between the different sample
groups, the Mann-Whitney nonparametric test was applied on RMA-
normalized data using the Statistical Package for Social Sciences, version
15.0 (SPSS, Inc, Chicago, IL). Data from qMSP and mRNA expres-
sion of TDRD1 were compared with the Spearman nonparametric
correlation test. Student’s t test was applied to evaluate differences in the
expression data obtained by quantitative real-time PCR (qRT-PCR).
P < .05 was considered statistically significant.
Results
Differential Expression Analysis in Primary Tumors
Expression array data allowed the identification of both specific and
shared ERG and ETV1 expression-associated genes (Figure 1). Distribu-
tion of samples according to the expression profile of the 22,000 genes
shows that the PCa samples form a unique cluster that deviates from
the expression profile found in the NPT control samples (Figure 2A).
Combined analysis of genes differentially expressed among the dif-
ferent sample groups (NPT, ETS-negative PCa, ERG-positive PCa
and ETV1-positive PCa) led to the identification of 57 genes spe-
cifically associated with PCa with ERG rearrangement (Table W2)
and 15 genes specifically associated with PCa with ETV1 rearrange-
ment (Table W3), with 27 genes being differentially expressed in
both PCa subgroups comparing to PCa without ETS rearrangements
and with NPT (Table W4). PCA using the expression data of the
99 genes thus selected shows four completely independent sample
clusters: NPT controls, ETS-negative PCa, ERG-positive PCa, and
ETV1-positive PCa (Figure 2B). Hierarchical clustering of the sam-
ples according to expression of the 99 genes and of ERG and ETV1
shows clear stratification according to the ETS rearrangement status
(Figure 2C). Interestingly, the two PCa with other ETS rearrangements
(involving ETV4 and ETV5) cluster in close proximity with ETV1-
positive PCa samples.
Selection of Target Genes for Validation in VCaP and
LNCaP Cell Line Models
Using the expression profile of VCaP, LNCaP, PC3, and DU145
cell lines available from Taylor et al. [30] (GSE21034), of our list of
57 ERG candidate target genes, only 7 (ATP8A2, CACNA1D, HLA-
DMB, PDE3B, PLA1A, SH3RF1, and TDRD1) were significantly
upregulated and 1 (TMBIM1) was significantly downregulated inVCaP
cells compared with the other cell lines (Figure W1). Following the
same approach, only 2 (FKBP10 and GLYATL2) of the 15 candidate
ETV1 target genes were significantly upregulated in LNCaP cells com-
paring with the other cell lines, and only 7 (CDC2L6, GRPR, KCNH8,
NCALD, PLA2G7, TMEM45B, and ZNF385B) of the 27 target genes
shared by ERG and ETV1 rearrangements were overexpressed at least
in one of the two ETS-positive cell lines comparing with PC3 and
DU145 (FigureW1). In silico analysis of the ChIP-Seq data set available
from Yu et al. [26] confirmed ERG binding to the promoter of both
the eight specific and the seven shared ERG candidate target genes in
VCaP cells (Table W5).
Figure 4. Validation of tumor-associated ETV1 target genes in cell line models. (A) Using shRNAs directed to ETV1, a significant down-
regulation of ETV1 expression was achieved in LNCaP cells, as evaluated both by qRT-PCR and by Western blot analyses. (B) FKBP10
andGLYATL2, two tumor-associated ETV1 candidate target genes,were shown to be significantly decreased after ETV1 silencing. (C)Denovo
expression of ETV1 was stably induced in the benign PNT2 prostate cells, as shown by qRT-PCR and Western blot analyses. (D) De novo
expression of ETV1 induced significant up-regulation of FKBP10 expression in the PNT2-ETV1-B cells, which show higher expression of
ETV1. (E) Box plot distribution of the expression of FKBP10 among the different sample groups shows a significant up-regulation of FKBP10
in ETV1-positive PCa comparing with other PCa and with NPT samples. **P < .01. NS indicates not significant (P > .05).
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Figure 5. Validation of shared ERG and ETV1 tumor-associated target genes in cell line models. (A and B) Quantitative expression analysis of
the seven ETS shared candidate target genes in ERG-downregulated VCaP cells and ETV1-downregulated LNCaP cells, respectively, shows
that GRPR, KCNH8, and TMEM45B are significantly downregulated after silencing of either ERG or ETV1. (C) Box plot distribution of the
expression of GRPR (left panel) and KCNH8 (right panel) among the different prostate sample groups shows significant up-regulation of
both genes in ERG- and ETV1-positive PCa comparing with ETS-negative PCa and with NPT samples. (D) qPCR of ERG-immunoprecipitated
chromatin from VCaP cells shows that ERG binds to the GRPR, KCNH8, and TMEM45B promoters. Only the promoter regions that gave
a relative enrichment value above the negative control are shown. (E) De novo expression of two ΔERG isoforms and of ETV1 was not
sufficient to induce expression of these genes in PNT2 cells. *P < .05. **P < .01. NS indicates not significant (P > .05).
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ERG-Dependent Deregulation of Tumor-Associated ERG
Target Genes in VCaP Cells
Quantitative expression analysis of the eight ERG candidate tar-
get genes after siRNA-mediated ERG silencing in VCaP cells shows that
expression of all genes but SH3RF1 is significantly affected by ERG
knockdown (Figure 3, A and B). De novo overexpression of the most
common ERG truncated isoforms (ΔERG and ΔERGΔ8) in the benign
prostate cell line PNT2, however, did not show the reverse effect (Fig-
ure 3, C and D). Expression levels of the seven deregulated ERG candi-
date target genes were not affected by ETV1 silencing in LNCaP cells
(data not shown), thus confirming that the observed ERG-dependent
regulation is specific of tumor cells harboring ERG overexpression.
Figure 6. Analysis of the topmost tumor-associated ERG target gene – TDRD1. (A) Box plot distribution of the nine prostate controls
(NPT) and the 48 PCa according to the expression of TDRD1 shows a significant P value comparing ERG-positive PCa with other PCa
and with NPT. (B) qPCR of ERG-immunoprecipitated chromatin from VCaP cells shows that ERG binds to two regions of the TDRD1
promoter. Only the promoter regions that gave a relative enrichment value above the negative control are shown. (C) Quantitative ex-
pression and methylation levels of TDRD1 in prostate controls and tumors show an inverse correlation (rs = −0.417, P = .0015). NPTs
are underlined in black, ETS-negative PCa in gray, ERG-positive PCa in red, and ETV1-positive PCa in purple. (D) Schematic representation
of the CpG island found in the TDRD1 promoter and of the methylation status of each CG dinucleotide in prostate cell lines. The location
of the primers used for bisulfite sequencing is shown by black arrows and the location of the primers and the TaqMan probe used for
qMSP is shown in blue. (E) Quantitative expression and methylation levels of TDRD1 in PNT2 cells show that de novo expression of two
ΔERG isoforms and of ETV1 does not increase the demethylation-induced expression of TDRD1 in the presence of DAC.
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ETV1 Overexpression Drives Up-regulation of the
Tumor-Associated Target FKBP10
A significant down-regulation of FKBP10 and GLYATL2 was
observed in the LNCaP-shETV1 clones (Figure 4, A and B). Inter-
estingly, de novo expression of full-length ETV1 in PNT2 cells showed
significant up-regulation of FKBP10 in the PNT2-ETV1-B population
(Figure 4C and 4D). These observations were not found in VCaP-
siERG cells neither in any of the PNT2-ERG cells (data not shown),
thus suggesting that ETV1 overexpression specifically drives FKBP10
up-regulation in prostate cells.
Shared Tumor-Associated ETS Target Genes Are Regulated
by Both ERG and ETV1 in Prostate Cancer Cell Lines
Quantification of the expression levels of the seven candidate target
genes shared by ERG and ETV1 rearrangements showed that GRPR,
KCNH8, and TMEM45B are significantly downregulated after silenc-
ing of both ETS transcription factors (Figure 5, A and B). Interest-
ingly, GRPR and KCNH8 were the topmost overexpressed genes of
our list of ERG and ETV1 shared candidate target genes (Figure 5C).
qPCR on the ERG-immunoprecipitated chromatin from VCaP cells
showed direct binding of ERG to the promoters of GRPR (region
−583), KCNH8 (region −1472), and TMEM45B (region −260)
(Figure 5D).
TDRD1 Expression Is Regulated by ERG in Prostate
Tumors Harboring ERG Rearrangement
Considering the highly significant association of our topmost over-
expressed gene, TDRD1, with PCa harboring ERG rearrangements
(Figure 6A), we first questioned whether TDRD1 was a direct target
of ERG. qPCR on the ERG-immunoprecipitated chromatin from
VCaP cells showed that ERG binds to the TDRD1 promoter in
two promoter regions (Figure 6B).
Because TDRD1 is described as a cancer germ line gene regulated
by methylation [31], we questioned whether methylation levels of
TDRD1 promoter differ among NPT control samples and the dif-
ferent subgroups of PCa of our series. A CpG island with 28 CpG
dinucleotides was found starting at −66 bp of the transcription start
site (Ensembl gene ID ENSG00000095627) and covering 330 bp
(Figure 6, C and D). As expected, a significant inverse correlation
was obtained between TDRD1 mRNA expression (exon array data,
linear values) and TDRD1 methylation levels (rs = −0.417, P = .0015).
A significant decrease in TDRD1 methylation was found between
tumors harboring ERG rearrangements and both NPT (P = .004) and
tumors without ETS rearrangements (P = .0001), whereas methyla-
tion levels of NPT and ETS-negative PCa were not statistically different
(P = .124).
Bisulfite sequencing of the TDRD1 promoter in VCaP, LNCaP,
PC3, DU145, 22Rv1, and PNT2 cells showed that the TDRD1 pro-
moter is completely methylated in all cell lines except in VCaP cells
(Figure 6D), the only cell line that shows expression of TDRD1 by
qRT-PCR (data not shown). Interestingly, the CpG island com-
pletely overlaps with the promoter region at −8768 bp shown to
be bound by ERG using ChIP. To evaluate whether ERG over-
expression modulates the levels of methylation-controlled TDRD1
expression in prostate cancer cells, we treated PNT2 cell populations
(PNT2-Neo, PNT2-ERG, and PNT2-ETV1) with epigenetic modu-
lating drugs. Treatment with DAC induced TDRD1 expression in
all PNT2 cells, and this reexpression was associated with decreased
methylation levels of the TDRD1 promoter (Figure 6E). These effects
were not observed when cells were treated with TSA alone, and neither
were they increased with the combination of TSA and DAC (data
not shown).
Discussion
We have analyzed a clinical series of PCa enriched for ERG and
ETV1 rearrangements with a genome-scale and exon-level expression
microarray platform that ensures robust gene-level expression measures.
Of 57 ERG-associated genes in primary PCa, 8 were also deregulated
in VCaP cells with the TMPRSS2-ERG fusion. In fact, seven of these
genes were shown to be significantly affected by ERG knockdown. Six
of these genes (PLA1A, CACNA1D, ATP8A2, HLA-DMB, PDE3B,
and TDRD1) have been previously described as coexpressed with
ERG in prostate cancer, but only PLA1A and CACNA1D are validated
as direct ERG target genes [12,18,32–35]. The top-ranked tumor-
associated ERG target gene in our study was TDRD1, and we showed
not only that TDRD1 expression is regulated by methylation of a CpG
island located at −66 bp of the transcription start site [31] but also that
ERG binds to the unmethylated CpG island of the TDRD1 promoter
in VCaP cells. Although ERG silencing in VCaP cells resulted in down-
regulation of TDRD1, our data on de novo overexpression of ERG in
PNT2 cells suggest that another regulatory mechanism acting upstream
of ERG actively leads to demethylation of TDRD1 promoter or that
other cofactors may be required for ERG-mediated TDRD1 demeth-
ylation. TDRD1 encodes the tudor domain-containing protein 1 de-
scribed as involved in male germ cell differentiation and in the small
RNAs pathway [36–38]. Although the biologic consequence of over-
expressed or reexpressed TDRD1 is not known, loss of TDRD1 in germ
line cells is associated with changes in small RNA profile and with
loss of methylation of L1 transposons [39] and may thus establish a
link between ERG overexpression and the epigenetic reprogramming
described by others [26,40,41].
Of the 15 genes highly associated with tumors harboring ETV1
rearrangements, only 2 genes were shown to have the expected over-
expression in the LNCaP cell line harboring an ETV1 rearrangement.
Both FKBP10 and GLYATL2 were significantly downregulated after
ETV1 knockdown, but only FKBP10 seemed to be upregulated in
PNT2 cells with de novo expression of ETV1. FKBP10 (FK506-binding
protein 10) encodes a member of the highly conserved family of intra-
cellular receptors called immunophilins, which acts as a molecular
chaperone in the endoplasmic reticulum [42]. We found no reports
on FKBP10 involvement in prostate carcinogenesis, but other immuno-
philins, namely FKBP51 and FKBP52, have been described to be
androgen regulated and their interaction with androgen receptor (AR)
seems to be necessary for AR-mediated proliferation of LNCaP cells
[43]. In the same cells, the presence of its ligand, FK506, was suffi-
cient to block several stages of the AR signaling [44]. Taken together,
these observations suggest that inhibition of FKBP10 by FK506 may be
a good therapy approach for the treatment of PCa harboring ETV1
rearrangements. Interestingly, when the expression profiles of the
two PCa with ETV4 and ETV5 rearrangements were included in the
hierarchical clustering, they clustered among the ETV1-positive PCa
samples. This suggests that theETV4 and ETV5 tumor-associated target
genes might be, at least in part, shared with ETV1, which, altogether,
represent the PEA3 subfamily of ETS transcription factors [45].
Although the identification of specific target genes of ERG and
ETV1 rearrangements in PCa is a major finding in this work, the
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existence of shared target genes was expected because both genes belong
to the same family of transcription factors [46]. In fact, we report a list
of 27 target genes shared by ERG and ETV1 rearrangements. KCNH8
and NCALD have been previously associated with tumors harbor-
ing ERG rearrangements [32–34], but no biologic validation of their
ERG dependence had been shown. Our results, using the VCaP and
LNCaP knockdown cell line models, clearly validate KCNH8, GRPR,
and TMEM45B as downstream targets of both ERG and ETV1, as
also indicated by our demonstration of direct binding of ERG to the
promoter of these genes using ERG-immunoprecipitated chromatin
from VCaP cells. TMEM45B encodes a putative membrane protein
with unknown function, so its role in prostate carcinogenesis might
be worth exploring. Nevertheless, GRPR, which encodes the gastrin-
releasing peptide receptor, has been described as overexpressed in
several cancer types, including PCa [47–51]. Overexpression of GRPR
was found in androgen-dependent prostate cancer xenografts [52], and
it seems to be dependent on AR activation [53]. Recently, Beer et al.
[50] described that combined overexpression of GRPR and AR was
associated with a favorable prognosis in patients with PCa. These
observations, together with our findings showing GRPR overexpres-
sion in a high proportion of PCa harboring either ERG or ETV1 re-
arrangements, warrant further investigation on the cooperation of ETS
transcription factors and AR signaling in regulating the expression of
GRPR in PCa.
Only a fraction of the ERG and ETV1 tumor-associated genes
showed the expected expression pattern in VCaP and LNCaP cell
lines, the best available in vitro models of ERG- and ETV1-positive
PCa. This by no means indicates that the remaining potential ETS
target genes found in primary tumors are not relevant for in vivo pros-
tate carcinogenesis; it may be that these cell lines have kept only the
part of the in vivo tumor-derived gene expression signature that was
advantageous for in vitro survival or the in vitro cell line–associated
gene expression signature is being modulated by the environmental
factors to which cells are exposed. In fact, our PCa series is derived
from organ confined or locally advanced tumors [8] removed by radical
prostatectomy before any other therapy, meaning that they were, most
probably, androgen responsive. Nevertheless, although VCaP and
LNCaP cells are androgen responsive [54,55], the gene expression sig-
nature available from Taylor et al. [30] and the ERG and ETV1 silenc-
ing experiments that were performed were obtained without androgen
stimulation. This suggests that the expression of some tumor-associated
ERG and ETV1 target genes might be dependent on androgen receptor
activation, whereas others might be androgen independent. The same
explanation may be operative with the overall absence of effect on the
tested target genes that was observed with de novo expression of either
ΔERG isoforms or ETV1 in the benign PNT2 cells, which are also
androgen sensitive [56]. Silencing and de novo expression of ERG and
ETV1 in these cell line models under androgen stimulation, together
with cell line–based assays focusing in specific ERG and ETV1 targets,
would be useful to clarify the cooperativity/dependence of these ETS
transcription factors and/or AR signaling.
In conclusion, differential expression profile of tumors harboring
either ERG or ETV1 rearrangements allowed the identification of both
specific and shared ETS downstream targets. From detailed studies in
prostate cancer models, we have validated ETS-dependent expression
of seven ERG-specific, two ETV1-specific, and three ERG and ETV1
shared target genes. TDRD1, FKBP10, and GRPR are promising
therapeutic targets and can serve as diagnostic markers for molecular
subtypes of PCa harboring specific fusion gene rearrangements.
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Table W1. Assay ID or Sequence of the Primers and Probes Used in This Study.
Assay Assay/Primer Name Assay ID/Primer Sequence 5′-3′
CDS-PCR ΔERG-F *CTAGGCGCCGGAATTCTAGGCGCGAGCTAAGCAGGAG
CDS-PCR ΔERG-R *CGGTAGAATTAGATCTTCCGATAGAGTTTGTGGCGATG
CDS-PCR ETV1-F *CTAGGCGCCGGAATTCAGCTGAGATTTGCGAAGAGC
CDS-PCR ETV1-R *CGGTAGAATTAGATCTGCCCTGCTTGACTGTCACTT
qRT-PCR ATP8A2 Hs00185259_m1
qRT-PCR CACNA1D Hs00167753_m1
qRT-PCR CDK19 Hs00292369_m1
qRT-PCR ERG Hs01554635_m1
qRT-PCR ETV1 Hs00951941_m1
qRT-PCR FKBP10 Hs00222557_m1
qRT-PCR GHR Hs01075601_m1
qRT-PCR GLYATL2 Hs00332757_m1
qRT-PCR GRPR Hs01055872_m1
qRT-PCR HLA-DMB Hs00157943_m1
qRT-PCR KCNH8 Hs00292491_m1
qRT-PCR NCALD Hs00230737_m1
qRT-PCR PDE3B Hs00265322_m1
qRT-PCR PLA1A Hs01056915_m1
qRT-PCR PLA2G7 Hs00173726_m1
qRT-PCR SH3RF1 Hs00325806_m1
qRT-PCR TDRD1 Hs00229805_m1
qRT-PCR TMBIM1 Hs00223351_m1
qRT-PCR TMEM45B Hs00431155_m1
qRT-PCR ZNF385B Hs00332216_m1
qRT-PCR GUSB 4333767F
qMSP TDRD1-F ATATTGAGTTGTACGTGGACGC
qMSP TDRD1-R GAATCCGAACCTATCTCTACGA
qMSP TDRD1-P CCTCGCCTCCAATCCCCAATACG
qMSP ACTB-F TGGTGATGGAGGAGGTTTAGTAAGT
qMSP ACTB-R AACCAATAAAACCTACTCCTCCCTTAA
qMSP ACTB-P ACCACCACCCAACACACAATAACAAACACA
BSP TDRD1-F TTGTAAAGGAATTTTTTGAGTTTG
BSP TDRD1-R CCTTCATACAAACCCTCTCC
ChIP-qPCR pTDRD1-1207F TCAGCCTGTCCCTTCAATTTAG
ChIP-qPCR pTDRD1-1207R CCCTCGAAAGTAGGGAACTCTT
ChIP-qPCR pTDRD1-3196F TGCTACAGTTTCTGGAGGTTCT
ChIP-qPCR pTDRD1-3196R TGCAATAGCCACAGGTGAAG
ChIP-qPCR pTDRD1-7686F GGTTCCACAGGAATGGAAGA
ChIP-qPCR pTDRD1-7686R TGTAAAATGCAGAGGGCAGTAG
ChIP-qPCR pTDRD1-8768F CCAAGTGACCTTCGAGGAGA
ChIP-qPCR pTDRD1-8768R GTCCACGTGCAACTCAATGT
ChIP-qPCR pKCNH8-797F GGATGGGCCTCACAACTAAC
ChIP-qPCR pKCNH8-797R TTGGAGAAAGGGAGGAGACA
ChIP-qPCR pKCNH8-1472F CCGAGTTCCTGGAGATCAGA
ChIP-qPCR pKCNH8-1472R ACCCAGAGCCCGAACTTTAT
ChIP-qPCR pKCNH8-3506F TGTGCTTGCTTTCAATCTGG
ChIP-qPCR pKCNH8-3506R CTTGGGGCTTCAGTTATTGG
ChIP-qPCR pGRPR-583F TGGGCAGTGATTGAAGTGTC
ChIP-qPCR pGRPR-583R GCACTGAGAAATCCTCAAATCC
ChIP-qPCR pGRPR-1386F TGGCTAAAGGTCTAAGCCTG
ChIP-qPCR pGRPR-1386R CGGCATTTTGATGCAGCTAT
ChIP-qPCR pGRPR-4858F TCCTTCCCTCACACCCTGTA
ChIP-qPCR pGRPR-4858R ATGCACCCACAGGTAACACC
ChIP-qPCR pTMEM45B-260F CCCCACCCTCATCCTTTTAT
ChIP-qPCR pTMEM45B-260R CCACGTTAAGAAGGATCAACAC
ChIP-qPCR pTMEM45B-2847F ACATGGATGCCACCAAGATT
ChIP-qPCR pTMEM45B-2847R GGGTCTCAGAGATCACTGCCTA
ChIP-qPCR pTMEM45B-5687F GGTGATGCCTGACAATGATG
ChIP-qPCR pTMEM45B-5687R AGCCACTTTCAACCCTTTCA
F indicates forward; P, probe (5′ FAM and 3′TAMRA); R, reverse.
*Underlined nucleotides are the In-fusion link for cloning, not gene specific.
Table W2. Tumor-Associated ERG-Specific Target Genes.
Gene Symbol Cytoband mRNA Accession Description
ACADVL 17p13-p11 NM_000018 Acyl-coenzyme A dehydrogenase, very long chain
ACER3 11q13.5 NM_018367 Alkaline ceramidase 3
ALDH2 12q24.2 NM_000690 Aldehyde dehydrogenase 2 family (mitochondrial)
ALOX15 17p13.3 NM_001140 Arachidonate 15-lipoxygenase
AMPD3 11p15 NM_001025390 Adenosine monophosphate deaminase (isoform E)
ANG 14q11.1-q11.2 NM_001145 Angiogenin, ribonuclease, RNAse A family, 5
ATP8A2 13q12 NM_016529 ATPase, aminophospholipid transporter-like, class I, type 8A, member 2
AUTS2 7q11.22 NM_015570 Autism susceptibility candidate 2
AZGP1 7q22.1 NM_001185 α-2-glycoprotein 1, zinc-binding
BCR 22q11|22q11.23 NM_004327 Breakpoint cluster region
C4orf18 4q32.1 NM_001128424 Chromosome 4 open reading frame 18
CACNA1D 3p14.3 NM_000720 Calcium channel, voltage-dependent, L-type, α 1D subunit
CD44 11p13 NM_000610 CD44 molecule (Indian blood group)
CDH7 18q22-q23 NM_033646 Cadherin 7, type 2
CLUL1 18p11.32 NM_014410 Clusterin-like 1 (retinal)
CRYM 16p13.11-p12.3 NM_001888 Crystallin, mu
CST3 20p11.21 NM_000099 Cystatin C
EFHD2 1p36.21 NM_024329 EF-hand domain family, member D2
FRK 6q21-q22.3 NM_002031 Fyn-related kinase
GDA 9q21.13 NM_004293 Guanine deaminase
GPRC5D 12p13.3 NM_018654 G protein-coupled receptor, family C, group 5, member D
HDAC1 1p34 NM_004964 Histone deacetylase 1
HLA-DMB 6p21.3 NM_002118 Major histocompatibility complex, class II, DM β
HPS1 10q23.1-q23.3 NM_000195 Hermansky-Pudlak syndrome 1
KAZALD1 10q24.31 NM_030929 Kazal-type serine peptidase inhibitor domain 1
KCNN2 5q22.3 NM_021614 Potassium intermediate/small conductance calcium-activated channel,
subfamily N, member 2
KCNS3 2p24 NM_002252 Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3
KIF16B 20p11.23 NM_024704 Kinesin family member 16B
LIMK2 22q12.2 NM_016733 LIM domain kinase 2
MAPK6 15q21 NM_002748 Mitogen-activated protein kinase 6
MCOLN2 1p22 NM_153259 Mucolipin 2
MCOLN3 1p22.3 NM_018298 Mucolipin 3
MPPED2 11p13 NM_001584 Metallophosphoesterase domain-containing 2
MUM1L1 Xq22.3 NM_152423 Melanoma-associated antigen (mutated) 1-like 1
MYO6 6q13 NM_004999 Myosin VI
OGDHL 10q11.23 NM_018245 Oxoglutarate dehydrogenase-like
PCDHB9 5q31 NM_019119 Protocadherin β 9
PDE3B 11p15.1 NM_000922 Phosphodiesterase 3B, cGMP-inhibited
PDP1 8q22.1 NM_001161778 Pyruvate dehyrogenase phosphatase catalytic subunit 1
PHLDB2 3q13.2 NM_001134438 Pleckstrin homology-like domain, family B, member 2
PLA1A 3q13.13-q13.2 NM_015900 Phospholipase A1 member A
PNKD 2q35 NM_015488 Paroxysmal nonkinesigenic dyskinesia
PRPS2 Xp22.3-p22.2 NM_001039091 Phosphoribosyl pyrophosphate synthetase 2
PRR15 7p14.3 NM_175887 Proline-rich 15
RAB27A 15q15-q21.1 NM_004580 RAB27A, member RAS oncogene family
RAB30 11q12-q14 NM_014488 RAB30, member RAS oncogene family
RICH2 17p12 NM_014859 Rho-type GTPase-activating protein RICH2
SEMA4G 10q24.31 NM_017893 Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM)
and short cytoplasmic domain, (semaphorin) 4G
SH3RF1 4q32.3-q33 NM_020870 SH3 domain-containing ring finger 1
SLCO1B3 12p12 NM_019844 Solute carrier organic anion transporter family, member 1B3
SMOC2 6q27 NM_022138 SPARC-related modular calcium binding 2
TDRD1 10q25.3 NM_198795 Tudor domain-containing 1
TMBIM1 2p24.3-p24.1 NM_022152 Transmembrane BAX inhibitor motif containing 1
TMEM134 11q13.2 NM_025124 Transmembrane protein 134
TMEM26 10q21.2 NM_178505 Transmembrane protein 26
VLDLR 9p24 NM_003383 Very low density lipoprotein receptor
ZNF217 20q13.2 NM_006526 Zinc finger protein 217
Table W3. Tumor-Associated ETV1-Specific Target Genes.
Gene Symbol Cytoband mRNA Accession Description
ACACA 17q21 NM_198839 Acetyl-coenzyme A carboxylase α
BOK 2q37.3 NM_032515 BCL2-related ovarian killer
COL9A2 1p33-p32 NM_001852 Collagen, type IX, α2
FKBP10 17q21.2 NM_021939 FK506 binding protein 10, 65 kDa
GLYATL2 11q12.1 NM_145016 Glycine-N -acyltransferase-like 2
MTNR1A 4q35.1 NM_005958 Melatonin receptor 1A
PROS1 3q11.2 NM_000313 Protein S (α)
SIPA1 11q13 NM_153253 Signal-induced proliferation–associated 1
SLC16A1 1p12 NM_003051 Solute carrier family 16, member 1 (monocarboxylic acid transporter 1)
SLC45A2 5p13.2 NM_016180 Solute carrier family 45, member 2
SLC4A10 2q23-q24 NM_022058 Solute carrier family 4, sodium bicarbonate transporter, member 10
SRGAP1 12q14.2 NM_020762 SLIT-ROBO Rho GTPase activating protein 1
SYT6 1p13.2 NM_205848 Synaptotagmin VI
TWIST1 7p21.2 NM_000474 Twist homolog 1 (Drosophila)
VSTM2L 20q11.23 NM_080607 V-set and transmembrane domain-containing 2 like
Table W4. Tumor-Associated ETS Shared Target Genes.
Gene Symbol Cytoband mRNA Accession Description
APLN Xq25-q26.3 NM_017413 Apelin
CDC2L6 6q21 NM_015076 Cell division cycle 2-like 6 (CDK8-like)
CHN2 7p15.3 NM_004067 Chimerin (chimaerin) 2
CLYBL 13q32 NM_206808 Citrate lyase β like
CSGALNACT1 8p21.3 NM_018371 Chondroitin sulfate N -acetylgalactosaminyltransferase 1
DLX1 2q32 NM_178120 Distal-less homeobox 1
FAM81A 15q22.2 NM_152450 Family with sequence similarity 81, member A
FANK1 10q26.2 NM_145235 Fibronectin type III and ankyrin repeat domains 1
FOXD1 5q12-q13 NM_004472 Forkhead box D1
GHR 5p13-p12 NM_000163 Growth hormone receptor (GHR), mRNA
GRPR Xp22.2-p22.13 NM_005314 Gastrin-releasing peptide receptor
KCNC2 12q14.1 NM_139136 Potassium voltage-gated channel, Shaw-related subfamily, member 2
KCNH8 3p24.3 NM_144633 Potassium voltage-gated channel, subfamily H (eag-related), member 8
MYO1E 15q21-q22 NM_004998 Myosin IE
NCALD 8q22.2 NM_001040624 Neurocalcin delta
NKAIN1 1p35.2 NM_024522 Na+/K+ transporting ATPase interacting 1
NOSTRIN 2q24.3-q31.1 NM_001039724 Nitric oxide synthase trafficker
PLA2G7 6p21.2-p12 NM_005084 Phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)
PPFIBP2 11p15.4 NM_003621 PTPRF interacting protein, binding protein 2 (liprin β2)
REXO2 11q23.1-q23.2 NM_015523 REX2, RNA exonuclease 2 homolog (Saccharomyces cerevisiae)
SDK1 7p22.2 NM_152744 Sidekick homolog 1, cell adhesion molecule (chicken)
SNX24 5q23.2 NM_014035 Sorting nexin 24
TMEM178 2p22.1 NM_152390 Transmembrane protein 178
TMEM45B 11q24.3 NM_138788 Transmembrane protein 45B
ZNF385B 2q31.2-q31.3 NM_152520 Zinc finger protein 385B
ZNF652 17q21.32-q21.33 NM_001145365 Zinc finger protein 652
ZNF765 19q13.42 NM_001040185 Zinc finger protein 765
Figure W1. Basal expression levels of the selected ETS target genes in VCaP, LNCaP, PC3, and DU145 cell lines, obtained from the
RMA-normalized signal intensity data publicly available from Taylor et al. [30] (GSE21034). (A) Basal expression levels of the eight tumor-
associated ERG-specific candidate target genes. (B) Basal expression levels of the two tumor-associated ETV1-specific candidate target
genes. (C) Basal expression levels of the seven tumor-associated ERG and ETV1 shared candidate target genes.
Table W5. ERG Binding Sites to the Selected Target Genes [26].
Target Coordinates (Peak) Peak Height Peak Width
ATP8A2 chr13:24,844,894-24,845,182 13.6548 289
chr13:24,960,106-24,960,310 10.6179 205
chr13:24,966,222-24,966,790 29.0745 569
chr13:24,967,021-24,967,552 51.4902 532
chr13:24,981,947-24,982,277 14.3591 331
chr13:24,968,575-24,968,953 12.2229 379
chr13:25,047,778-25,047,926 10.0191 149
chr13:25,159,694-25,160,317 18.6479 624
chr13:25,435,965-25,436,267 12.0351 303
chr13:25,443,584-25,443,980 16.0235 397
chr13:25,450,401-25,450,626 12.8697 226
chr13:25,492,200-25,492,681 22.8975 482
CACNA1D chr3:53,494,975-53,495,558 93.0446 583
chr3:53,543,934-53,544,673 25.4475 740
chr3:53,503,125-53,503,899 15.0684 775
chr3:53,515,374-53,515,828 24.2029 455
chr3:53,623,475-53,623,677 11.7889 203
CDC2L6 chr6:111,243,178-111,243,861 18.2715 684
chr6:111,051,167-111,051,366 12.5119 200
chr6:111,241,751-111,241,952 14.04 202
chr6:111,117,200-111,117,567 119.945 368
GRPR chrX:16,051,325-16,051,526 10.369 202
HLA-DMB chr6:33,017,157-33,017,600 21.7845 444
KCNH8 chr3:19,163,071-19,164,838 62.0921 1768
chr3:19,233,172-19,233,503 21.5962 332
chr3:19,272,826-19,273,052 11.42 227
NCALD chr8:103,206,257-103,206,743 37.8902 487
chr8:103,204,576-103,205,659 11.8456 1084
chr8:103,190,344-103,190,556 11.8066 213
chr8:103,189,323-103,190,009 23.2166 687
chr8:103,186,224-103,186,529 12.561 306
chr8:103,112,338-103,112,871 76.5726 534
chr8:103,049,066-103,049,534 29.0425 469
chr8:102,838,398-102,838,910 26.5179 513
chr8:102,822,392-102,822,919 13.4375 528
chr8:102,805,976-102,806,202 11.6241 227
PDE3B chr11:14,621,513-14,622,267 24.9654 755
chr11:14,622,401-14,623,083 12.3038 683
PLA1A chr3:120,802,377-120,802,558 11.5989 182
PLA2G7 chr6:46,811,125-46,811,459 10.8366 335
SH3RF1 chr4:170,427,905-170,429,255 30.7452 1351
chr4:170,377,325-170,377,452 10.7175 128
chr4:170,272,975-170,273,177 10.1184 203
chr4:170,261,789-170,262,253 26.2919 465
chr4:170,250,579-170,250,860 13.09 282
TDRD1 chr10:115,928,777-115,929,226 42.7532 450
chr10:115,929,474-115,929,753 17.2206 280
chr10:115,931,749-115,931,952 12.9605 204
TMBIM1 chr2:218,845,599-218,846,084 15.9441 486
chr2:218,842,616-218,843,563 68.8155 948
TMEM45B chr11:129,190,576-129,191,309 26.0991 734
chr11:129,192,367-129,192,815 16.6449 449
chr11:129,227,301-129,227,768 16.9834 468
chr11:129,228,731-129,229,530 28.771 800
ZNF385B chr2:180,434,051-180,434,374 10.9614 324
chr2:180,251,300-180,251,534 12.105 235
chr2:180,250,103-180,250,510 19.5634 408
